Nkarta, Inc.
corporate_fare Company Profile
Nkarta, Inc. (NASDAQ:NKTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for NKTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for NKTX spans 8-K, 10-Q, 424B5, S-3.
Recent high-impact activity:
- Nkarta's NKX019 Hits 83% Myositis, 86% SSc Responses With Zero CRS/ICANS/GvHD
- Nkarta Posts $40.4M Q2 Loss, Cash Runway Into 2029; Key Trial Data Expected This Year
- Nkarta Reports Q1 2026 Financials, Extends Cash Runway to 2029, and Advances NKX019 Clinical Program
- Nkarta Extends Cash Runway into 2029, Reports Q1 Results, and Advances Clinical Trials
- FDA Greenlights Outpatient Dosing for Nkarta's NKX019, Expanding Autoimmune Market Access
Financial Snapshot
Short Interest & Short Volume
2.87 days to coverFINRA reported short interest of 3,839,406 shares in NKTX as of the October 30, 2026 settlement, a 12.1% increase from the prior period — about 2.9 days to cover at its recent average daily volume. On November 20, 2026, 58.0% of NKTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.